Cutaneous reactions to epidermal growth factor receptor inhibitors

Journal of Drugs in Dermatology

Volumn 9, Issue 10, 2010, Pages 1229-1234

  Pomerantz, Rebecca G ^a   Mirvish, Ezra D ^a   Geskin, Larisa J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; DOXYCYCLINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETRETIN; GEFITINIB; GEMCITABINE; HYDROCORTISONE; IMMUNOMODULATING AGENT; IRINOTECAN; ISOTRETINOIN; MATUZUMAB; MEPREDNISONE; METRONIDAZOLE; MINOCYCLINE; NIMOTUZUMAB; PANITUMUMAB; PIMECROLIMUS; RETINOID DERIVATIVE; SUNSCREEN; TAZAROTENE; TITANIUM DIOXIDE; ZALUTUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ABDOMEN; ARTICLE; ASTHENIA; BUTTOCK; CANCER SURVIVAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EYELASH; FACE; FOLLICULITIS; HAIR; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; HYPERPIGMENTATION; KIDNEY CARCINOMA; LIMB; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MALE TYPE ALOPECIA; NAUSEA; PANCREAS CANCER; PARONYCHIA; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; SCALP; SCALP HAIR; SCAR FORMATION; SECONDARY INFECTION; SIDE EFFECT; SKIN CARE; SKIN FISSURE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; VOMITING; XEROSIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; RASH; REVIEW;

DRUG ERUPTIONS; EXANTHEMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78049519723     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10:345-356. (Pubitemid 40647253)
2. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169-1176. (Pubitemid 34204207)
3. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279. (Pubitemid 32591445)
4. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55:657-670. (Pubitemid 44436627)
5. Pomerantz RG, Chirinos RE, Falo LD, Jr., et al. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol. 2008;144:949-950. (Pubitemid 352039757)
6. Sipples R. Common side effects of anti-EGFR therapy: Acneiform rash. Semin Oncol Nurs. 2006;22:28-34. (Pubitemid 43564198)
7. Lynch TJ Jr., Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist. 2007;12:610-621. (Pubitemid 350012125)
8. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598-601. (Pubitemid 35015303)
9. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res. 2003;9:2478-2486. (Pubitemid 36842087)
10. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124. (Pubitemid 34032602)
11. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803-812. (Pubitemid 44450468)
12. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-26.
13. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-1433. (Pubitemid 41222414)
14. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500. (Pubitemid 40903630)
15. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 2005;23:5235-5246. (Pubitemid 46224035)
16. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132. (Pubitemid 41058344)
18. Senderowicz AM, Johnson JR, Sridhara R, et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park). 2007;21:1696-1706.
19. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208. (Pubitemid 41079832)
20. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22:3003-3015. (Pubitemid 41103711)
21. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664. (Pubitemid 46797944)
22. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10:1212-1218. (Pubitemid 38365209)
23. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646-1654. (Pubitemid 41079803)
24. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol Ther. 2006;5:375-379.
25. Allan DG. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist. 2005;10:760-761. (Pubitemid 41567290)
26. Kolesar J, Brahmer J, Lee J, et al. Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2007;25:7588-.
27. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol (Meeting Abstracts). 2007;25:4037-.
28. Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology. 2007;72:152-159. (Pubitemid 351161602)
29. Molinari E, De Quatrebarbes J, Andre T, et al. Cetuximab-induced acne. Dermatology. 2005;211:330-333. (Pubitemid 41642106)
30. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21:34-36.
31. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500-505. (Pubitemid 46273854)
32. Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005;153:849-851. (Pubitemid 41415923)
33. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-5396. (Pubitemid 350232214)
34. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
35. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980-988. (Pubitemid 47312862)
36. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85. (Pubitemid 41095117)
37. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2. J Clin Oncol. 2004;22:785-794. (Pubitemid 41103589)